Two studies published April 18 in the journal Cell have shined new light on the role genetics can play in developing obesity—or protecting against it.

The 71-year-old Framingham Heart Study has received $38 million from the National Heart, Lung, and Blood Institute to fund a new six-year study into the biology of aging.

The first study to test an experimental antiplatelet compound in humans found the therapy inhibited clot formation without increasing bleeding, suggesting it could avoid that dangerous side effect of other clot-preventing drugs.

The popular diabetes drug metformin reversed left ventricular hypertrophy (LVH) in a randomized trial of patients with coronary artery disease but without diabetes, suggesting a potential new use for the medication.

Percutaneous coronary intervention is being offered to a greater proportion of older adults with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock over the past two decades—a trend that’s been paralleled by declining mortality rates, according to a study in the Journal of the American College of Cardiology.

Three physicians published an editorial in Stroke proposing that tertiary healthcare centers in cities be held to stricter standards for performing endovascular thrombectomy (EVT) than their rural counterparts.

The same genetic variants that have been uncovered in patients with two other types of cardiomyopathy are also present in an uncommonly high proportion of people with cancer therapy-induced cardiomyopathy (CCM), researchers reported in Circulation.

The FDA has cleared Gelesis100 hydrogel capsules to be used as a weight management aid alongside diet and exercise in adults with body mass indexes (BMIs) ranging from 25 to 40, according to an April 14 press release from the product’s manufacturer.